Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.65 |
| ▸ | PRKDC | P78527 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586846 | 0.85 | ATR (0.57) | ATRPRKDCMAPK1IKBKETBK1 | |
| SCHEMBL3462566 | 0.80 | ATR (0.66) | ATRPRKDC | |
| SCHEMBL2483700 | 0.80 | ATR (1.00) | ATRPRKDC | |
| SCHEMBL23703155 | 0.79 | ATR (0.64) | ATRPRKDCACVR1 | |
| SCHEMBL23732912 | 0.78 | ATR (0.63) | ATRPRKDCACVR1 | |
| SCHEMBL4928363 | 0.78 | ATR (0.63) | ATRPRKDCACVR1 | |
| SCHEMBL27912649 | 0.77 | ATR (0.50) | ATRMAPK1ADORA3ADORA2AADORA2B | |
| SCHEMBL2484432 | 0.77 | ATR (0.67) | ATR | |
| SCHEMBL7845928 | 0.76 | ATR (0.45) | ATRMAPK1 | |
| SCHEMBL23389767 | 0.76 | ATR (0.57) | ATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580207-B1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-8703768-B2 | Nitrogen containing heteroaryl compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8623866-B2 | — | — | 2014-01-07 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2580207-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154327-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2066676-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | PDE10A, PDE3A, PDE2A | ATR 2553/4885PRKDC 3769/4885MAPK1 2131/4885 |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | MET, RET, ABL1 | ATR 1468/4885PRKDC 29/4885MAPK1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.